Literature DB >> 319066

Somatic cell hybrids between human lymphoma lines. III. Surface markers.

G Klein, P Terasaki, R Billing, R Honig, M Jondal, A Rosén, J Zeuthen, G Clements.   

Abstract

Hybrids between two human lymphoma lines, Raji and Daudi (8A) and Raji BJAB (83) were examined for genetically determined and/or differentiation-related surface markers. HL-A B ce-l alloantigens, Fc and complement receptors, EBV receptors and beta2 microglobulin showed an autonomous ("co-dominant") expression in the hybrid. This is in contrast to most previous studies on other differentiation markers, involving as a rule crosses between cells of different lineages, where the differentiated pattern usually became "eclipsed" in the hybrid. Staining of activated complement and complement consumption tests showed intermediate or partially suppressed expression in the hybrids. This may be viewed in relation to the fact that these reactions do not merely depend on complement binding to the receptor, but also on subsequent activation and binding of the activated complement. A more complex interaction is also suggested for immunoglobulin production. Surface immunoglobulin showed a suppressive or intermediate pattern in both hybrids, whereas intracellular kappa chain production showed an amplification in the 83 hybrid. The beta2 microglobulin deficiency of the Daudi parent was corrected in the Raji/Daudi hybrid. Two new HL-A specificities,A10 and BW17, appeared on this hybrid which were not present on the parental lines. This suggests that the HL-A deficiency of the Daudi cell is due to its lack of beta2 microglobulin.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 319066     DOI: 10.1002/ijc.2910190110

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  10 in total

1.  Expression of members of immunoglobulin gene family in somatic cell hybrids between human B and T cells.

Authors:  D Kozbor; R Burioni; A Ar-Rushdi; C Zmijewski; C M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  1987-07       Impact factor: 11.205

2.  Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids.

Authors:  R D Salter; D N Howell; P Cresswell
Journal:  Immunogenetics       Date:  1985       Impact factor: 2.846

Review 3.  Cell-surface-antigen mutants of haematopoietic cells. Tools to study differentiation, biosynthesis and function.

Authors:  R Hyman
Journal:  Biochem J       Date:  1985-01-01       Impact factor: 3.857

Review 4.  Mutations that influence the secretory path in animal cells.

Authors:  A M Tartakoff
Journal:  Biochem J       Date:  1983-10-15       Impact factor: 3.857

Review 5.  Epstein-Barr virus (EBV), lymphocytes and transformation.

Authors:  J Zeuthen
Journal:  J Cancer Res Clin Oncol       Date:  1983       Impact factor: 4.553

6.  Organization and expression of immunoglobulin genes in fetal liver hybridomas.

Authors:  R P Perry; D E Kelley; C Coleclough; J F Kearney
Journal:  Proc Natl Acad Sci U S A       Date:  1981-01       Impact factor: 11.205

7.  Identification of human genomic clones coding the major histocompatibility antigens HLA-a2 and HLA-B7 by DNA-mediated gene transfer.

Authors:  J A Barbosa; M E Kamarck; P A Biro; S M Weissman; F H Ruddle
Journal:  Proc Natl Acad Sci U S A       Date:  1982-10       Impact factor: 11.205

8.  HLA antigen structural gene mutants selected with an allospecific monoclonal antibody.

Authors:  D Pious; M S Krangel; L L Dixon; P Parham; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1982-12       Impact factor: 11.205

9.  The absence of beta 2-microglobulin in Daudi cells: active gene but inactive messenger RNA.

Authors:  C de Préval; B Mach
Journal:  Immunogenetics       Date:  1983       Impact factor: 2.846

10.  Association of the H-Y male antigen with beta2-microglobulin on human lymphoid and differentiated mouse teratocarcinoma cell lines.

Authors:  M Fellous; E Günther; R Kemler; J Wiels; R Berger; J L Guenet; H Jakob; F Jacob
Journal:  J Exp Med       Date:  1978-07-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.